Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | TSLP | Q969D9 | 10/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25458001 | 0.91 | CACNA1B (0.46) | KEAP1CACNA1BSSTR1SSTR2SSTR4 | |
| SCHEMBL25455154 | 0.90 | CACNA1B (0.61) | KEAP1CACNA1BSSTR1SSTR2SSTR4 | |
| SCHEMBL25456785 | 0.87 | KEAP1 (0.55) | KEAP1CACNA1BSSTR1SSTR2SSTR4 | |
| SCHEMBL25455153 | 0.87 | PLAU (0.47) | KEAP1CACNA1BSSTR1SSTR2SSTR4 | |
| SCHEMBL25456827 | 0.81 | CACNA1B (0.53) | CACNA1BSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL25456105 | 0.79 | PLAU (0.42) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19232193 | 0.76 | CACNA1B (0.56) | CACNA1BSSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL29557412 | 0.75 | KEAP1 (0.59) | KEAP1PLAUKLKB1ACE2 | |
| SCHEMBL19232199 | 0.74 | CACNA1B (0.65) | KEAP1CACNA1BSSTR1SSTR2SSTR4 | |
| SCHEMBL15082201 | 0.74 | CACNA1B (0.56) | KEAP1CACNA1BCTSGPLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | QUANTUM INTELLIGENCE CORP. (KR) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145835-A1 | Modulators of Alpha-4-beta-7 Integrin and MAdCAM | ITGB7, ITGAM, ITGA4 | KEAP1 4862/4885CACNA1B 952/4885SSTR1 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.